EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic Profiling Using 3H-Labeled Eggshell Membrane and Effects of Eggshell Membrane and Lysozyme Oral Supplementation on DSS-Induced Colitis and Human Gut Microbiota

Miho Shimizu iD, Wataru Sugai, Eri Ohto-Fujita, Aya Atomi, Norio Nogawa, Koichi Takamiya iD, Hisao Yoshinaga, Yoshihide Asano iD, Takashi Yamashita, Shinichi Sato, Atsushi Enomoto, Nozomi Hatakeyama und 7 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26189102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Miho Shimizu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Material Health Science, Graduate School of Engineering, Tokyo University of Agriculture and Technology, Tokyo 184-8588, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Muramidase, Colitis, Egg Shell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eggshell membrane (ESM) is composed of approximately 90% protein. Our previous studies in healthy adults demonstrated that two months of daily ESM intake improved respiratory function, zigzag walking speed, and skin elasticity. The present study aims to address the knowledge gap regarding the in vivo effects of ESM in the context of inflammatory bowel disease (IBD). Proteomic analysis was performed on powdered ESM used as a dietary supplement. To investigate its pharmacokinetics in mice, tritium (3H)-labeled ESM was prepared using the 6Li(n,α)3H nuclear reaction. The therapeutic potential of ESM was further examined in a 2.0% dextran sulfate sodium (DSS)-induced murine model of IBD. In addition, fecal samples from both mice and healthy human subjects were analyzed using a modified terminal restriction fragment length polymorphism (T-RFLP) method. Lysozyme C (LYZ) was the most abundant protein (47%), followed by lysyl oxidase (12%) in ESM used in this study. 3H-ESM was mixed with MediGel, and orally administered to mice. Radioactivity levels were measured in blood, organs (duodenum, small intestine, large intestine, liver, kidney, lung, skin), and rectal feces at 0.5, 2, 5, 24, 48, and 72 h post-administration. Radioactivity in feces indicated excretion of undigested components, while systemic distribution suggested potential whole-body effects of ESM. Oral ESM and LYZ significantly alleviated body weight loss, diarrhea, and hematochezia in a DSS-induced murine model of IBD, leading to a significantly lower disease activity index on day 3 and showing a similar trend on day 5. Gut microbiota analysis showed increased Bacteroidales in the DSS group, while the ESM + DSS group maintained levels similar to the control. In humans, a double-blind, randomized controlled trial was conducted to evaluate the effects of ESM on gut microbiota in healthy adults. Participants received either ESM or placebo for 8 weeks. revealed a significant increase in alpha diversity at weeks 1 and 8 in the ESM group (p < 0.05), with between-group differences evident from week 1 (p < 0.01). ESM intake reduced Bacteroides and significantly increased Bifidobacterium and Lactobacillales at weeks 4 and 8. These findings suggest ESM supplementation promotes beneficial modulation of gut microbiota. These findings suggest that ESM, through its major protein components such as LYZ, may serve as a promising dietary intervention for maintaining intestinal health and mitigating inflammation in the context of IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeMuramidaseColitisEgg ShellAnimalsHumansMiceDietary SupplementsMaleFemaleDextran SulfateAdultAdministration, OralDisease Models, AnimalMiddle AgedFeces

Stichwörter der Autor:innen

BifidobacteriumLactobacillalesdextran sulfate sodium (DSS) colitiseggshell membrane (ESM)gut microbiotainflammatory bowel disease (IBD)intestinal fibrosislysozyme (LYZ)

Substanzen

Dextran SulfateMuramidase

Autor:innen und Institutionen

  • Material Health Science, Graduate School of Engineering, Tokyo University of Agriculture and Technology, Tokyo 184-8588, Japan.
  • Division of Applied Chemistry, Graduate School of Engineering, Tokyo University of Agriculture and Technology, Tokyo 184-8588, Japan.
  • Isotope Science Center, The University of Tokyo, Tokyo 113-0032, Japan.
  • Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan.
  • Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
  • Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.

ORCID-Profile: Miho Shimizu, Koichi Takamiya, Yoshihide Asano, Kazuya Tanaka, Tomoaki Atomi, Toshiyuki Watanabe, Yoriko Atomi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Shimizu, M., Sugai, W., Ohto-Fujita, E., Atomi, A., Nogawa, N., Takamiya, K., Yoshinaga, H., Asano, Y., Yamashita, T., Sato, S., Enomoto, A., Hatakeyama, N., Yasuda, S., Tanaka, K., Atomi, T., Harada, K., Hasebe, Y., Watanabe, T., & Atomi, Y. (2025). Pharmacokinetic Profiling Using 3H-Labeled Eggshell Membrane and Effects of Eggshell Membrane and Lysozyme Oral Supplementation on DSS-Induced Colitis and Human Gut Microbiota. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26189102

Vancouver

Shimizu M, Sugai W, Ohto-Fujita E, Atomi A, Nogawa N, Takamiya K, et al. Pharmacokinetic Profiling Using 3H-Labeled Eggshell Membrane and Effects of Eggshell Membrane and Lysozyme Oral Supplementation on DSS-Induced Colitis and Human Gut Microbiota. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26189102

BibTeX
@article{Shimizu2025,
  author = {Shimizu, Miho and Sugai, Wataru and Ohto-Fujita, Eri and Atomi, Aya and Nogawa, Norio and Takamiya, Koichi and Yoshinaga, Hisao and Asano, Yoshihide and Yamashita, Takashi and Sato, Shinichi and Enomoto, Atsushi and Hatakeyama, Nozomi and Yasuda, Shunsuke and Tanaka, Kazuya and Atomi, Tomoaki and Harada, Kenji and Hasebe, Yukio and Watanabe, Toshiyuki and Atomi, Yoriko},
  title = {Pharmacokinetic Profiling Using 3H-Labeled Eggshell Membrane and Effects of Eggshell Membrane and Lysozyme Oral Supplementation on DSS-Induced Colitis and Human Gut Microbiota},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26189102}
}
Kostenlos starten →